Oric Pharmaceuticals ORIC
$7.36 −$0.34 (-4.42%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.37 +0.14%
Open$7.58
Prev close$7.70
Day range$7.28 – $8.00
Volume1.46M
Market cap$764.94M
P/E (TTM)–
Dividend yield–
ORIC Stock News
Headlines matching Oric Pharmaceuticals or the ORIC ticker, most recent first.
- BTIG Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $26
- J.P. Morgan Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $23
- A Quick Look at Today's Ratings for Oric Pharmaceuticals(ORIC.US), With a Forecast Between $14 to $25
- H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Raises Target Price to $27 Positive
- HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $27 Positive
- HC Wainwright & Co. Reiterates Buy on ORIC Pharmaceuticals, Maintains $25 Price Target
- Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15
- Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (ARDT), Tactile Systems Technology (TCMD) and Oric Pharmaceuticals (ORIC)
- Piper Sandler Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $22
- H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
- Stifel Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $14
- Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $14
- Wells Fargo Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25
- Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
- Goldman Sachs Initiates Oric Pharmaceuticals(ORIC.US) With Buy Rating
No comments yet — be the first to weigh in on ORIC.
Sign in to join the discussion.